The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program
Abstract
Objective.— To evaluate safety and efficacy of onabotulinumtoxinA (BOTOX ® ) as headache prophylaxis in adults with chronic migraine. Background.— Chronic migraine is a prevalent, disabling, and undertreated neurological disorder. OnabotulinumtoxinA is the only approved prophylactic therapy in this highly disabled patient population. Design and Methods.— Two phase III, 24‐week, double‐blind, parallel‐group, placebo‐controlled studies, followed by a 32‐week, open‐label, single‐treatment, onabotulinumtoxinA phase, were conducted (January 23, 2006 to August 11, 2008). Qualified subjects were randomized (1:1) to injections of onabotulinumtoxinA (155‐195 U) or placebo every 12 weeks for 5 cycles (double‐blind: 2, open‐label: 3). The pooled primary variable was mean change from baseline in frequency of headache days. Secondary variables included proportion of patients with severe Headache Impact Test‐6 score (≥60) and mean changes from baseline in frequencies of migraine days, moderate/severe headache days, and migraine episodes; cumulative hours of headache on headache days; and acute headache medication intakes. The primary time point was week 24. Assessments for the open‐label phase (all patients treated with onabotulinumtoxinA) compared double‐blind treatment groups (onabotulinumtoxinA/onabotulinumtoxinA vs placebo/onabotulinumtoxinA) and are summarized to give a descriptive view of consistent study results, with inferences regarding statistical significance only examined for week 56. Results.— A total of 1384 patients were randomized to onabotulinumtoxinA (n = 688) or placebo (n = 696) in the double‐blind phase; 607 (88.2%) onabotulinumtoxinA/onabotulinumtoxinA and 629 (90.4%) placebo/onabotulinumtoxinA patients continued into the open‐label phase. OnabotulinumtoxinA/onabotulinumtoxinA treatment statistically significantly reduced headache‐day frequency vs placebo/onabotulinumtoxinA in patients with chronic migraine at week 56 (−11.7 onabotulinumtoxinA/onabotulinumtoxinA, −10.8 placebo/onabotulinumtoxinA; P = .019). Statistically significant reductions also favored onabotulinumtoxinA/onabotulinumtoxinA for several secondary efficacy variables at week 56, including frequencies of migraine days (−11.2 onabotulinumtoxinA/onabotulinumtoxinA, −10.3 placebo/onabotulinumtoxinA; P = .018) and moderate/severe headache days (−10.7 onabotulinumtoxinA/onabotulinumtoxinA, −9.9 placebo/onabotulinumtoxinA; P = .027) and cumulative headache hours on headache days (−169.1 onabotulinumtoxinA/onabotulinumtoxinA, −145.7 placebo/onabotulinumtoxinA; P = .018). After the open‐label phase (all treated with onabotulinumtoxinA), statistically significant within‐group changes from baseline were observed for all efficacy variables. Most patients (72.6%) completed the open‐label phase; few discontinued because of adverse events. No new safety or tolerability issues emerged. Conclusions.— Repeated treatment with ≤5 cycles of onabotulinumtoxinA was effective, safe, and well tolerated in adults with chronic migraine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
New Appendix Criteria Open for a Broader Concept of Chronic Migraine
Olesen, J., Bousser, M.-G., Diener, H.-C., Dodick, D., First, M., Goadsby, P., Göbel, H., Lainez, M., Lance, J., Lipton, R., et al. (2006) · Cephalalgia · doi:10.1111/j.1468-2982.2006.01172.x · Cited by 909 · cited 11×
“Key words: botulinum toxin A, chronic migraine, prophylaxis Abbreviations: AE adverse event, CI confidence interval, CM chronic migraine, DB double-blind, HIT-6 Headache Impact Test-6, HRQoL health-related quality of life, ICHD-II International Classification of Headache Disorders, IMMPACT Initiative on Methods, Measu…”
BackgroundInfluentialTopiramate in the Treatment of Chronic Migraine
Silvestrini, M., Bartolini, M., Coccia, M., Baruffaldi, R., Taffi, R., & Provinciali, L. (2003) · Cephalalgia · doi:10.1046/j.1468-2982.2003.00592.x · Cited by 162
Cited by
Chronic migraine: risk factors, mechanisms and treatment
May, A., & Schulte, L. H. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.93 · Cited by 630
Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention
Lipton, R. B., & Silberstein, S. D. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12505_2 · Cited by 322
Bigal, M. E., Dodick, D. W., Rapoport, A. M., Silberstein, S. D., Ma, Y., Yang, R., Loupe, P. S., Burstein, R., Newman, L. C., & Lipton, R. B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00249-5 · Cited by 287
Leffler, D. A., Kelly, C. P., Green, P. H. R., Fedorak, R. N., DiMarino, A., Perrow, W., Rasmussen, H., Wang, C., Bercik, P., Bachir, N. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.008 · Cited by 263
Bigal, M. E., Edvinsson, L., Rapoport, A. M., Lipton, R. B., Spierings, E. L. H., Diener, H.-C., Burstein, R., Loupe, P. S., Ma, Y., Yang, R., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00245-8 · Cited by 261
Self-citation
Metadata
- Authors
- Aurora, S. K., Winner, P., Freeman, M. C., Spierings, E. L., Heiring, J. O., DeGryse, R. E., VanDenburgh, A. M., Nolan, M. E., & Turkel, C. C.
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 2011-08-29
- Volume
- 51
- Issue
- 9
- Pages
- 1358-1373
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W1994481205
- Cited by
- 295
- References
- 3
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program. https://app.cochat.ai/papers/10.1111/j.1526-4610.2011.01990.x
- The paper
- Aurora, S. K., Winner, P., Freeman, M. C., Spierings, E. L., Heiring, J. O., DeGryse, R. E., VanDenburgh, A. M., Nolan, M. E., & Turkel, C. C. (2011). OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2011.01990.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.